Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 271-279

  DeFeo Jones, Deborah ^a   Barnett, Stanley F ^a   Fu, Sheng ^a   Hancock, Paula J ^a   Haskell, Kathleen M ^a   Leander, Karen R ^a   McAvoy, Elizabeth ^a   Robinson, Ronald G ^a   Duggan, Mark E ^a   Lindsley, Craig W ^a   Zhao, Zhijian ^a   Huber, Hans E ^a   Jones, Raymond E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CELL PROTEIN; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B ALPHA; PROTEIN KINASE B BETA; PROTEIN KINASE B GAMMA; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CASPASES; CHROMONES; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MORPHOLINES; NEOPLASMS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 20044370874     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vivanco I, Sawyers CL. The phosphatidyl-inositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
2. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999;91:1922-32.
3. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
4. Yamada KM, Masaru A. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Science 2001;114: 2375-82.
5. Stiles B, Gilman V, Khanzenzon N, Lesche R, et al. Essential role of Akt-1/protein kinase Bα in PTEN-controlled tumorigenesis. Mol Cell Biol 2002;22:3842-51.
6. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19:2324-30.
7. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Can Res 2002;8:1100-06.
8. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high gleason grade prostate cancer. Clin Can Res 2002;8:1168-71.
9. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 2001;20: 1981-89.
10. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Brit J Can 2002;86:540-5.
11. Shi W, Zhang X, Pintilie M, et al. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 2003;104: 195-203.
12. Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002; 21:3532-40.
13. Roy HK, Olusola BF, Clemens DL, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-05.
14. Itoh N, Semba S, Ito M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94: 3127-34.
15. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 2001;292:1728-31.
16. Cho H, Thorvaldsen J L, Chu Q, Feng F, Birnbaum M J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001; 276:38349-52.
17. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and incresed apoptosis in mice with homozygous disruption of the Akt1 gene. Genes & Development 2001;15:2203-08.
18. Yang ZZ., Tschopp O, Baudry A, Dummler BB, Hynx D, Hemmings BA. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004;32: part 2:350-54.
19. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bγ with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999;274:9133-36.
20. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999;68: 965-1014.
21. Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem 2002;277:3743-51.
22. Barnett S, DeFeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin homology domain dependent and isozyme specific Akt inhibitors. Biochem J 2005;385:399-408.
23. Nakatani N, Thompson DA, Barthel A et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
24. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276:10767-74.
25. Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. The Prostate 2002;52:1-11.
26. Wendel H-G, de Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428: 332-37.
27. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotoc and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
28. Mills, GB, Lu, Y, Fang, X, et al. The role of genetic abnormalities of PTEN and the phosphatidyl inositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001;28:125-41.
29. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.